In recent years, antibody drugs targeting PD-1/PD-L1 have made great breakthroughs in clinical practice, and are known as the most successful ‘broad-spectrum anti-cancer drug target in history (29, 47, 48). The gene discussed is PDCD1; the disease is cancer.